HK1247123A1 - 治疗copd和其它炎症性病况的组合物和方法 - Google Patents
治疗copd和其它炎症性病况的组合物和方法 Download PDFInfo
- Publication number
- HK1247123A1 HK1247123A1 HK18106856.0A HK18106856A HK1247123A1 HK 1247123 A1 HK1247123 A1 HK 1247123A1 HK 18106856 A HK18106856 A HK 18106856A HK 1247123 A1 HK1247123 A1 HK 1247123A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- active agent
- pde4b
- pde4b2
- expression
- pka
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136115P | 2015-03-20 | 2015-03-20 | |
| US62/136,115 | 2015-03-20 | ||
| PCT/US2016/023475 WO2016154143A1 (en) | 2015-03-20 | 2016-03-21 | Compositions and methods for treating copd and other inflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1247123A1 true HK1247123A1 (zh) | 2018-09-21 |
Family
ID=56979181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18106856.0A HK1247123A1 (zh) | 2015-03-20 | 2016-03-21 | 治疗copd和其它炎症性病况的组合物和方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11045456B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3270921A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6960855B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107427500A (cg-RX-API-DMAC7.html) |
| HK (1) | HK1247123A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016154143A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005020958A2 (en) | 2003-08-26 | 2005-03-10 | Research Development Foundation | Aerosol delivery of curcumin |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| US20100316631A1 (en) * | 2006-10-19 | 2010-12-16 | The Uab Research Foundation | Water Soluble Curcumin-Based Compounds |
| US20100074897A1 (en) | 2006-12-01 | 2010-03-25 | University Of Utah Research Foundation | Methods and Compositions related to HIF-1 alpha |
| CN102300568A (zh) * | 2008-12-05 | 2011-12-28 | 赢泰医药科技发展有限公司 | Hif-1蛋白积聚的抑制剂 |
| US20130172303A1 (en) | 2012-01-03 | 2013-07-04 | Forest Laboratories Holdings Ltd. | Roflumilast compositions for the treatment of copd |
| US9951335B2 (en) * | 2012-04-10 | 2018-04-24 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD |
-
2016
- 2016-03-21 CN CN201680016932.2A patent/CN107427500A/zh active Pending
- 2016-03-21 EP EP16769518.8A patent/EP3270921A4/en not_active Withdrawn
- 2016-03-21 WO PCT/US2016/023475 patent/WO2016154143A1/en not_active Ceased
- 2016-03-21 US US15/559,728 patent/US11045456B2/en not_active Expired - Fee Related
- 2016-03-21 JP JP2017548049A patent/JP6960855B2/ja not_active Expired - Fee Related
- 2016-03-21 HK HK18106856.0A patent/HK1247123A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3270921A1 (en) | 2018-01-24 |
| WO2016154143A8 (en) | 2017-09-28 |
| CN107427500A (zh) | 2017-12-01 |
| EP3270921A4 (en) | 2018-09-19 |
| JP2018510153A (ja) | 2018-04-12 |
| US20180042904A1 (en) | 2018-02-15 |
| WO2016154143A1 (en) | 2016-09-29 |
| JP6960855B2 (ja) | 2021-11-05 |
| US11045456B2 (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease | |
| US20230092181A1 (en) | Intermittent dosing of mdm2 inhibitor | |
| US20080269123A1 (en) | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases | |
| Susuki-Miyata et al. | Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi | |
| JP2022078996A (ja) | 重篤なインフルエンザの治療又は予防のための方法及び化合物 | |
| US20120294956A1 (en) | Inhibition of dynamin related protein 1 to promote cell death | |
| Lawrence et al. | E3 ubiquitin ligase NKLAM ubiquitinates STAT1 and positively regulates STAT1-mediated transcriptional activity | |
| Lei et al. | PARP (Poly ADP‐ribose Polymerase) family in health and disease | |
| Connolly et al. | Caffeine modulates CREB-dependent gene expression in developing cortical neurons | |
| JP2021535152A (ja) | 神経変性障害を処置するためのripキナーゼの阻害法 | |
| US20230026808A1 (en) | Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury | |
| Qin et al. | Protective effect of Sirt1 against radiation-induced damage | |
| WO2020154520A1 (en) | Methods of treating epilepsy via phosphodiesterase 4 (pde4) inhibition | |
| US9963701B2 (en) | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor | |
| US9951335B2 (en) | Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD | |
| Gu et al. | Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay | |
| Luo et al. | PRMT1 in health and disease: Emerging perspectives from molecular mechanisms to therapeutic strategies | |
| Wang et al. | Schisantherin A interacts with gut bacteria to stimulate adipose tissue thermogenesis in obese mice via a TGR5‒p-CREB‒STAT6 signaling pathway | |
| US10189795B2 (en) | Aryl amine substituted quinoxaline used as anticancer drugs | |
| CN1980681A (zh) | GSK-3β的调节及治疗增殖性病变的方法 | |
| CN107921028A (zh) | 治疗葡萄膜黑素瘤的mdm2抑制剂 | |
| US11045456B2 (en) | Compositions and methods for treating COPD and other inflammatory conditions | |
| WO2025059029A1 (en) | Methods of treating vexas syndrome | |
| Na et al. | Itraconazole attenuates hepatic gluconeogenesis and promotes glucose uptake by regulating AMPK pathway | |
| WO2017143070A1 (en) | Combination therapy |